Klinikum der Universität München

Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases (2025) Mravinacová S, Bergström S, Olofsson J, de San José NG, Anderl-Straub S, Diehl-Schmid J, Fassbender K, et al. Journal article PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma (2025) Zeremski V, Haage TR, Witte HM, Adolph L, Beer SA, Behre G, Jacobs B, et al. Journal article Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor (2025) Wegert J, Appenzeller S, Treger TD, Streitenberger H, Ziegler B, Bausenwein S, Vokuhl C, et al. Journal article Use of sedative drugs in specialist palliative care (iSedPall): a multi-modal intervention pilot study protocol (2025) Ostgathe C, Bausewein C, Schildmann E, Bazata J, Heckel M, Kauzner S, Klein C, et al. Journal article Correction to: Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals (BMC Medicine, (2024), 22, 1, (346), 10.1186/s12916-024-03548-z) (2025) Liwinski T, Auer MK, Schröder J, Pieknik I, Casar C, Schwinge D, Henze L, et al. Journal article, Erratum Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease – Design and rationale of the randomized COMPLETE-NSTEMI trial (2025) Feistritzer HJ, Jobs A, Zeymer U, Schneider S, Lauten P, Ferenc M, Weferling M, et al. Journal article Maternal experience of fetal movements from a child with AMC: MECA survey (2025) Arduç A, Linskens IH, Dussa CU, van Bosse H, Lemin S, Sawatzky B, Filges I, De Vries JI Journal article Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study (2025) Mahajan UM, Oehrle B, Goni E, Strobel O, Kaiser J, Grützmann R, Werner J, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma (2025) Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, et al. Journal article